What is Acute Myelogenous Leukemia (AML)?
Acute Myelogenous Leukemia (AML) is a rapidly progressing cancer of the myeloid blood cell line that interferes with the normal production of white blood cells, red blood cells, and platelets. It most commonly affects adults but can also occur in children.
Role of Stem Cell Therapy:
HSCT is a common treatment for AML in patients who do not respond to chemotherapy or have a high risk of relapse. It enables the use of high-dose therapy to eradicate leukemic cells and restore healthy blood formation.
Medical Insight:
Allogeneic HSCT offers the best chance for long-term remission, particularly in patients with unfavorable genetic profiles or relapsed disease. The timing and donor match are critical factors.
Source: Leukemia & Lymphoma Society: https://www.lls.org/treatment/types-treatment/stem-cell-transplantation
Why consider stem cell storage for Acute Myelogenous Leukemia (AML)?
AML can require immediate intervention. Storing stem cells provides a ready resource for faster access to life-saving treatment.
